Who Generates Higher Gross Profit? Pfizer Inc. or BioMarin Pharmaceutical Inc.

Pfizer vs. BioMarin: A Decade of Gross Profit Dominance

__timestampBioMarin Pharmaceutical Inc.Pfizer Inc.
Wednesday, January 1, 201462127600040028000000
Thursday, January 1, 201573788700039203000000
Friday, January 1, 201690723400040495000000
Sunday, January 1, 2017107186000041306000000
Monday, January 1, 2018117594800042399000000
Tuesday, January 1, 2019134458200041531000000
Wednesday, January 1, 2020133618300033216000000
Friday, January 1, 2021137576000050467000000
Saturday, January 1, 2022161237000065986000000
Sunday, January 1, 2023184216100028809000000
Monday, January 1, 202445776000000
Loading chart...

Data in motion

A Tale of Two Giants: Pfizer Inc. vs. BioMarin Pharmaceutical Inc.

In the ever-evolving landscape of pharmaceuticals, the battle for supremacy in gross profit generation is a captivating narrative. From 2014 to 2023, Pfizer Inc. consistently outperformed BioMarin Pharmaceutical Inc., with Pfizer's gross profit peaking at an impressive $66 billion in 2022. This figure dwarfs BioMarin's highest gross profit of approximately $1.8 billion in 2023.

Pfizer's dominance is evident, with its gross profit averaging around 35 times that of BioMarin over the decade. However, BioMarin's steady growth, with a 196% increase from 2014 to 2023, showcases its resilience and potential in the niche market of rare diseases.

As the pharmaceutical industry continues to innovate, these financial insights provide a glimpse into the strategic maneuvers of two industry titans, each carving its path in the global market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025